updated earnings outlook reflects significantly higher input cost inflation and lower sales volumes.
q2 reflects continued pandemic-driven volatility.
facing significantly higher input costs and a reversal in consumer tissue volumes from record growth in year ago period.
moved decisively to take pricing actions to mitigate inflationary headwinds and continue to prudently manage costs.
sees 2021 net sales increase 1 to 4 percent.
